🔗 Share this article

Given that America undertakes historic revisions to its vaccination schedules, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by questioning coronavirus vaccines throughout the pandemic and has focused upon alleged deaths after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Program

Agency leaders had intended to reveal major revisions to the pediatric immunization program in December, bringing the US with Denmark’s national calendar, sources say – a major change that would place the US out of alignment with much of the global community with little proof for improved outcomes. The planned update has been pushed back until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth person to lead the center this calendar year.

A Shift at the Regulatory Body

This interim role might represent a closer partnership between the pharmaceutical and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending some pediatric shot schedules in the US in order to be more like Denmark, a society with comprehensive healthcare and a citizenry approximately the size of Wisconsin’s.

To date comments, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Background

Høeg has little discernible track record in drug development, regulation or leadership, which has been standard for former directors of the biologics center. She has served at the FDA as a top consultant to the FDA chief and CBER since March.

“It seems she lacks to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a major agency. She has no expertise in pharmaceutical oversight.”

Previous directors of the center would “grasp legal statutes and the science of drug development”, commented Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

This division has an immense portfolio at the FDA, she pointed out.

“Everybody just focuses on the innovative therapies, but the generic program clears numerous generic drugs. There’s a biologic copycat branch, non-prescription drug unit and more, and all of those have to be supervised,” Dr. Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a substantial administrative element to the role, which manages over 5,000 staff members. “It’s a massive management job, if you execute it properly,” the former official added.

Official Statement and Disputed Policies

When asked about concerns about Høeg’s qualifications and whether this selection represents greater collaboration among agency officials on immunizations, a press secretary said that the “questions rely on inaccurate presumptions”.

“Her experience is consistent with the duties of her job,” the representative explained, pointing to the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg takes over the agency head's new expedited review system, a disputed one-day medication authorization process that allegedly troubled her preceding directors. “By what process are these medications being chosen for this voucher program? Who is making the choices?” Dr. Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards less stringent oversight of all drugs, aside from shots.”

Documented Track Record on Immunizations

With vaccines, Høeg has a more documented, if problematic, history, Howard said. She published a research paper using unconfirmed crowd-sourced reports to determine the incidence of myocarditis after COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the incoming administration featured altering regulations for new vaccines and halting “unnecessary” immunizations, she remarked after the election on a online show. At the agency, Høeg has reportedly proposed preventing teenage boys from receiving COVID-19 vaccinations.

“She is an complete dogmatist who begins with her beliefs and reverse-engineers to retrofit the evidence in a highly misleading, fraudulent manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|